

Surrey & North West Sussex Area Prescribing Committee

<b>Policy Statement</b>	Ustekinumab for treating active psoriatic arthritis
<b>Policy No:</b>	PCN 167-2015
<b>Date of Issue</b>	September 2015
<b>Review Date:</b>	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p><b>Recommendations:</b> The PCN recommends Ustekinumab as a treatment option for treating active Psoriatic Arthritis in adults in line with NICE TA340.</p>	
<p><b>Key Considerations:</b></p> <ul style="list-style-type: none"> <li>NICE TA 340 <a href="https://www.nice.org.uk/guidance/ta340/resources/ustekinumab-fortreating-active-psoriatic-arthritis-rapid-review-of-technology-appraisal-guidance313-82602601123525">https://www.nice.org.uk/guidance/ta340/resources/ustekinumab-fortreating-active-psoriatic-arthritis-rapid-review-of-technology-appraisal-guidance313-82602601123525</a></li> <li>The Psoriatic Arthritis Pathway has been updated to include Ustekinumab as a treatment option</li> </ul> <p><b>Post PCN meeting note: (December 2016) The PCN should be aware that the consequence of the publication of this NICE TA is that there is a cohort of patients who will have received all the lines of biologic treatment in the pathway but will now be eligible for treatment with Ustekinumab as per the NICE TA.</b></p>	
<b>Date taken to Area Prescribing Committee</b>	Virtual decision September 2015
<b>Agreed by APC members</b>	December 2016